IGF1R and non-small cell lung carcinoma: After the failures of two large randomized phase III anti-IGF1R trials in NSCLC, (Figitumumab [13], hR1507 [13,14]), IR-A signaling has been postulated as one of the major mediators of resistance to anti-IGF1R therapy [11,15].